HBL – Hadasit Bio Holdings Ltd.
January 1, 2015
Securities Authority Tel Aviv Stock Exchange Ltd.
Re: Extension of Option Period regarding the License Agreement between Teva and CellCure Neurosciences
Further to the immediate report of the Company dated October 10, 2010 (reference no.: 2010-01-640794), regarding the signature of the agreement between CellCure Neurosciences Ltd. (hereinafter: “CellCure”), a company held 21.2% by the Company, and between Teva Pharmaceutical Industries Ltd. (hereinafter: “Teva”), based on which CellCure has granted Teva an option to receive a global and exclusive license to develop and commercialize the OpRegen® product of CellCure for treatment of patients with dry age-related retinal degeneration ( Dry AMD) (hereinafter: the “Option”), as of October 18, 2010 and until 60 days after the approval of the IND by the FDA, the Company would like to announce as follows:
After discussions between CellCure and Teva, it has been agreed to extend the term of the Option by thirty additional days, such that the total exercise period is 90 days, as of the date of the approval of the IND by the FDA.
This report related, further to the Company’s report dated November 2, 2014, to the receipt of approval of the IND by the FDA (reference no.: 2014-01-185499).
HBL – Hadasit Bio-Holdings Ltd.
By: Mrs. Tamar Kfir, CEO